Linden Thomas Advisory Services’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.43M Buy
27,150
+607
+2% +$80K 0.28% 93
2026
Q1
$3.7M Sell
26,543
-23,010
-46% -$3.22M 0.36% 71
2025
Q4
$6.08M Buy
49,553
+1,279
+3% +$155K 0.62% 22
2025
Q3
$5.36M Buy
48,274
+747
+2% +$84.9K 0.54% 31
2025
Q2
$5.27M Buy
47,527
+1,630
+4% +$173K 0.58% 29
2025
Q1
$5.14M Buy
45,897
+1,366
+3% +$141K 0.67% 18
2024
Q4
$4.11M Buy
44,531
+1,630
+4% +$147K 0.52% 28
2024
Q3
$3.6M Buy
42,901
+847
+2% +$64.6K 0.49% 36
2024
Q2
$2.89M Buy
42,054
+7,084
+20% +$473K 0.45% 44
2024
Q1
$2.56M Buy
34,970
+836
+2% +$64.3K 0.41% 47
2023
Q4
$2.77M Buy
34,134
+2,153
+7% +$168K 0.52% 27
2023
Q3
$2.4M Buy
31,981
+10,511
+49% +$808K 0.53% 22
2023
Q2
$1.65M Buy
21,470
+594
+3% +$47.4K 0.37% 75
2023
Q1
$1.73M Buy
20,876
+2,048
+11% +$170K 0.43% 63
2022
Q4
$1.62M Buy
+18,828
New +$1.49M 0.46% 61

Other funds holding GILD

Linden Thomas Advisory Services's GILD Position: Q2 2026 in Review

Linden Thomas Advisory Services increased its Gilead Sciences (GILD) stake by 2.3% in Q2 2026, buying an estimated $80K and bringing the position to 27,150 shares worth $3.43M. The position accounts for 0.28% of the portfolio, ranked #93.

Linden Thomas Advisory Services first reported a position in GILD in Q4 2022 and has held it in 15 quarters since. The position peaked at $6.08M in Q4 2025. 690 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Linden Thomas Advisory Services held 27,150 shares of Gilead Sciences worth $3.43M as of Q2 2026.
  • Linden Thomas Advisory Services bought 607 Gilead Sciences shares in Q2 2026, an estimated $80K.
  • Gilead Sciences made up 0.28% of Linden Thomas Advisory Services's portfolio in Q2 2026, its #93 holding.
  • Linden Thomas Advisory Services first reported a position in Gilead Sciences in Q4 2022 and has held it in 15 quarters since.
  • Linden Thomas Advisory Services's Gilead Sciences position peaked at $6.08M in Q4 2025.
  • 690 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Linden Thomas Advisory Services's 13F filing for Q2 2026, filed 16 Jul 2026.